All that is necessary for the practical implementation of our findings in the routine clinical practice are acquiring and employing three antibodies targeting ASCL1, NEUROD1, and POU2F3, in addition to employing CD8 staining—a well-established technique in lymphoma diagnosis. This evidence concerns the gene ASCL1 and lymphoma.